If you only glanced at Alector’s headline figures, the story might look confusing. Total revenue was US$7.874 million in Q2 2025 and US$3.32 million in Q2 2026, while the firm’s net loss narrowed from US$30.524 million to US$22.99 million. For Alector shareholders, the return over the past year was 49.3%, including dividends. If you had been weighing a position back in November 2025, what exactly were you being paid to believe about this business? The easy part of this move is behind Alector...
Alector holds steady despite trial failures, pivoting to ABC platform, and Roche deal extends cash to 2029. Read why ALEC stock is a Hold.
Detailed price information for Alector Inc (ALEC-Q) from The Globe and Mail including charting and trades.
Alector (ALEC) stock jumps after a $75M equity offering priced at $2.05/share. Read more here.
Detailed price information for Alector Inc (ALEC-Q) from The Globe and Mail including charting and trades.
Detailed price information for Alector Inc (ALEC-Q) from The Globe and Mail including charting and trades.
Detailed price information for Mckesson Corp (MCK-N) from The Globe and Mail including charting and trades.
Detailed price information for CVS Corp (CVS-N) from The Globe and Mail including charting and trades.
Detailed price information for Alector Inc (ALEC-Q) from The Globe and Mail including charting and trades.
Alector’s approach combines an engineered GCase with the biotech’s blood-brain barrier delivery platform.
Real-time index price for TSX Venture Composite Index (JX), along with buy or sell indicators, analysis, charts, historical performance, news and more
Alector will receive $100 million upfront and could earn up to $1. 17 billion in additional milestones while Genentech assumes responsibility for developing and commercializing AL050 globally.
Alector stock jumps 22% after Genentech/Roche licenses AL050 for Parkinson’s. Read more here.
The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and CSL cut licensing deals and the FDA endorsed broader use of a Lilly medicine.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026 (New York, New York)Thursday, September 10, 2026, at 2:10 p.m. ET, fireside chat Morgan Stanley 24th Annual Global Healthcare Conference (N
This is the newest page. Registered accounts read further back.